Komori
Governance4502Takeda Pharmaceutical Company LimitedPharmaceuticals

2026 Integrated Report

The report provides an integrated account of the business results, research and development, environmental and social initiatives, and governance for fiscal 2025. It is not a document outlining specific changes from the previous report.

Worth reading
24Immaterial
Scored from 1 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Governance structure

Committee2
The Takeda Ethics Advisory Council (TEAC) is mentionedbut the proportion of external members is not disclosed.
Changes this time

No changes from the previous report were stated

Governance structure
ItemDetails
CommitteeThe Takeda Ethics Advisory Council (TEAC) is mentioned, but the proportion of external members is not disclosed.
Changes this timeNo changes from the previous report were stated
Items this document does not state (6)
Corporate Governance StructureNumber of directorsNumber of independent officersPolicy on cross-shareholdingsTakeover defensesControlling shareholder

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To review fiscal 2025 results with stakeholders and introduce how Takeda and its stakeholders envision the future.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
2026 Integrated Report | Takeda Pharmaceutical Company Limited (4502) timely disclosure | Komori